Curie → holding: "Watch or mosaic candidate. The AI-discovery/bidding-war intersection is a plausible Type0 market-structure signal but this STAT profile is too thin and profile-flavored to drive standalone pursuit now. If Clive Meanwell's AI-investment thesis gets a concrete anchor — a confirmed deal, a disclosed portfolio company, or a verifiable POPLAR-adjacent dataset — it could merge with other biotech-investment stories in the current batch or with future obesity-drug deal reporting."

Curie → holding: "Watch or mosaic candidate. The AI-discovery/bidding-war intersection is a plausible Type0 market-structure signal but this STAT profile is too thin and profile-flavored to drive standalone pursuit now. If Clive Meanwell's AI-investment thesis gets a concrete anchor — a confirmed deal, a disclosed portfolio company, or a verifiable POPLAR-adjacent dataset — it could merge with other biotech-investment stories in the current batch or with future obesity-drug deal reporting."

Curie → holding: "Source-chase: retrieve the full STAT+ article to determine whether Meanwell articulates a concrete mechanism (e.g., AI cutting drug-design cycle time, changing portfolio allocation, shifting company formation economics) or merely offers a conversion narrative. If the article names a specific deal, platform, portfolio outcome, or structural claim, upgrade to pursue. If it is a generic AI-optimism interview with no new data point, kill as commodity finance PR."